BiotechTube

Abemaciclib + Placebo + Abiraterone acetate + Prednisone

Phase 2/3Active
1 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prostate Cancer

Conditions

Prostate Cancer

Trial Timeline

Nov 26, 2018 → Jun 1, 2026

NCT ID
NCT03706365

About Abemaciclib + Placebo + Abiraterone acetate + Prednisone

Abemaciclib + Placebo + Abiraterone acetate + Prednisone is a phase 2/3 stage product being developed by Eli Lilly for Prostate Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT03706365. Target conditions include Prostate Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Prostate Cancer were approved

Approved (20) Terminated (4) Active (0)
✅EnzalutamideAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enzalutamide + Androgen deprivation therapy (ADT)Astellas PharmaApproved
✅Enzalutamide + Abiraterone + Placebo for Enzalutamide + PrednisoneAstellas PharmaApproved
✅EnzalutamideAstellas PharmaApproved
✅Enzalutamide + FlutamideAstellas PharmaApproved
✅LeuprolideAstellas PharmaApproved

Hype Score Breakdown

Clinical
15
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03706365Phase 2/3Active

Competing Products

20 competing products in Prostate Cancer

See all competitors
ProductCompanyStageHype Score
NBTXR3 activated by IMRT only + NBTXR3 activated by Brachytherapy & IMRTNanobiotixPhase 1/2
18
PemetrexedEli LillyPhase 2
35
5 mg Tadalafil + Placebo + 0.2 mg TamsulosinEli LillyPhase 3
40
SRF617 + etrumadenant + zimberelimabCoherus BioSciencesPhase 2
17
eFT508eFFECTOR TherapeuticsPhase 2
17
EnhertuDaiichi SankyoPhase 2
42
Ifinatamab deruxtecan + Docetaxel + Prednisone + Rescue MedicationDaiichi SankyoPhase 3
47
exatecan mesylateDaiichi SankyoPhase 2
35
PLX3397Daiichi SankyoPhase 2
27
Valemetostat + DarolutamideDaiichi SankyoPhase 1
36
Enzalutamide + Placebo + Androgen deprivation therapy (ADT)Astellas PharmaPhase 3
44
EnzalutamideAstellas PharmaPhase 2
35
Enzalutamide + Docetaxel + Prednisolone + PlaceboAstellas PharmaPhase 3
40
EnzalutamideAstellas PharmaPhase 2
35
Enzalutamide + Metformin HydrochlorideAstellas PharmaPhase 1
29
degarelix + GoserelinAstellas PharmaPhase 3
40
Enzalutamide, 160mg, 40 mg soft capsules, once dailyAstellas PharmaPre-clinical
26
enzalutamide + abiraterone acetate + prednisoneAstellas PharmaPhase 2
35
enzalutamide + abiraterone acetate + prednisone + Leuprolide acetateAstellas PharmaPhase 2
42
YM155Astellas PharmaPhase 2
35